DC10022 |
PF06840003
|
PF-06840003 is an orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1),with potential immunomodulating and antineoplastic activities. |
DC8021 |
Indoximod (NLG-8189)
|
NLG-8189 is an inhibitor of IDO and INDOL1 (IDO2) |
DC7015 |
INCB024360 analogue(IDO-IN-1)
|
INCB024360 is a potent IDO1 inhibitor(IC50=10 nM) with desirable pharmaceutical properties, which is poised to start clinical trials in cancer patients. |
DC10421 |
IDO-IN-2
|
IDO-IN-2 is an IDO inhibitor extracted from patent WO/2015031295 A1, compound example 1, has IC50 values of 0.068 μM in HeLa cell and 0.16 μM in HEK293 cell. |
DC10098 |
IDO-IN-1
|
IDO-IN-1 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50 of 59 nM, shows activity in Hela cell (IC50=12 nM). |
DC8389 |
Epacadostat (INCB024360)
|
Epacadostat (INCB024360) is a potent and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor with IC50 of 10 nM. Phase 2. |
DC10131 |
BMS-986205(Linrodostat)
|
BMS-986205 is an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic activity, alone and in combination with nivolumab in advanced cancers in a phase 1/2a trial |